Serological Responses to the First Three Doses of SARS-CoV-2 Vaccination in Inflammatory Bowel Disease: A Prospective Cohort Study
Abstract
Background
Individuals with inflammatory bowel disease (IBD) who are immunocompromised may have a reduced serological response to the SARS-CoV-2 vaccine. We investigated serological responses following 1st, 2nd, and 3rddoses of SARS-CoV-2 vaccination in those with IBD.
Methods
A prospective cohort study of persons with IBD (n= 496) assessed serological response 1–8 weeks after 1stdose vaccination, 1–8 weeks after 2nddose, 8 or more weeks after 2nddose, and at least 1 week after 3rddose. Seroconversion and geometric mean titer (GMT) with 95% confidence intervals (CI) were assessed for antibodies to the SARS-CoV-2 spike protein. Multivariable linear regression models assessed the adjusted fold change (FC) in antibody levels.
Results
Seroconversion and GMT increased from post-1stdose to 1–8 weeks post-2nddose (81.6%, 1814 AU/mL vs. 98.7%, 9229 AU/mL,p<0.001), decreased after 8 weeks post-2nddose (94.9%, 3002 AU/mL,p<0.001), and rebounded post-3rddose (99.6%, 14639 AU/mL,p<0.001). Prednisone was the only IBD-related medication associated with diminished antibody response after 3rd-dose vaccination (FC: 0.07 [95% CI: 0.02, 0.20]). Antibody levels steadily decline following the 2nd(FC: 0.92 [95% CI: 0.90, 0.94] per week) and 3rddose (FC: 0.88 [95% CI: 0.84, 0.92] per week) of the SARS-CoV-2 vaccine.
Conclusion
A three-dose regimen of vaccination to SARS-CoV-2 yields a robust antibody response for those with IBD across all classes of IBD therapies except for prednisone. The decaying antibody levels following the 3rddose of the vaccine should be monitored in future studies.
Related articles
Related articles are currently not available for this article.